(Q30790259)

26 June 2017

1 reference

title

Glatiramer acetate (Copaxone) therapy for multiple sclerosis (English)

1 reference

26 June 2017

Glatiramer acetate (Copaxone®) therapy for multiple sclerosis (English)

1 reference

https://api.crossref.org/works/10.1016/S0163-7258(03)00036-6

29 December 2023

0 references

1 reference

https://api.crossref.org/works/10.1016/S0163-7258(03)00036-6

29 December 2023

author name string

Suhayl Dhib-Jalbut

series ordinal

1

1 reference

26 June 2017

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=12725872

29 December 2023

publication date

1 May 2003

1 reference

full work available at URL

26 June 2017

https://api.elsevier.com/content/article/PII:S0163725803000366?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/S0163-7258(03)00036-6

https://api.elsevier.com/content/article/PII:S0163725803000366?httpAccept=text/plain

29 December 2023

1 reference

https://api.crossref.org/works/10.1016/S0163-7258(03)00036-6

Pharmacology & Therapeutics

29 December 2023

published in

1 reference

26 June 2017

volume

98

1 reference

26 June 2017

issue

2

1 reference

26 June 2017

page(s)

245-255

1 reference

Copolymer 1 induces T cells of the T helper type 2 that crossreact with myelin basic protein and suppress experimental autoimmune encephalomyelitis

26 June 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900036-6

7 January 2021

Copolymer 1 acts against the immunodominant epitope 82-100 of myelin basic protein by T cell receptor antagonism in addition to major histocompatibility complex blocking

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900036-6

7 January 2021

Specific Th2 cells accumulate in the central nervous system of mice protected against experimental autoimmune encephalomyelitis by copolymer 1

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900036-6

7 January 2021

The development of Cop 1 (Copaxone), an innovative drug for the treatment of multiple sclerosis: personal reflections

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900036-6

7 January 2021

New insights into the mechanism of action of copolymer 1 in experimental allergic encephalomyelitis and multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900036-6

7 January 2021

The autoimmune reactivity to myelin oligodendrocyte glycoprotein (MOG) in multiple sclerosis is potentially pathogenic: effect of copolymer 1 on MOG-induced disease

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900036-6

7 January 2021

Multiple sclerosis: trial of a synthetic polypeptide

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900036-6

7 January 2021

A pilot trial of Cop 1 in exacerbating-remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900036-6

7 January 2021

A placebo-controlled, double-blind, randomized, two-center, pilot trial of Cop 1 in chronic progressive multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900036-6

7 January 2021

Humoral and cellular immune responses to Copolymer 1 in multiple sclerosis patients treated with Copaxone

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900036-6

7 January 2021

Failure of copolymer I to inhibit the human T-cell response to myelin basic protein

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900036-6

7 January 2021

Sustained immunological effects of Glatiramer acetate in patients with multiple sclerosis treated for over 6 years

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900036-6

7 January 2021

Two types of mouse helper T cell clone. III. Further differences in lymphokine synthesis between Th1 and Th2 clones revealed by RNA hybridization, functionally monospecific bioassays, and monoclonal antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900036-6

7 January 2021

European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900036-6

7 January 2021

Glatiramer acetate (copolymer-1)-specific, human T cell lines: cytokine profile and suppression of T cell lines reactive against myelin basic protein

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900036-6

7 January 2021

Mechanisms of action of interferons and glatiramer acetate in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900036-6

7 January 2021

Glatiramer acetate (Copaxone) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900036-6

7 January 2021

Suppression of experimental allergic encephalomyelitis by chemically modified encephalitogen

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900036-6

7 January 2021

Glatiramer acetate reduces the proportion of new MS lesions evolving into "black holes".

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900036-6

7 January 2021

Role of magnetic resonance imaging in the diagnosis and monitoring of multiple sclerosis: consensus report of the White Matter Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900036-6

7 January 2021

Direct binding of myelin basic protein and synthetic copolymer 1 to class II major histocompatibility complex molecules on living antigen-presenting cells--specificity and promiscuity.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900036-6

7 January 2021

Synthetic amino acid copolymers that bind to HLA-DR proteins and inhibit type II collagen-reactive T cell clones

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900036-6

7 January 2021

Glatiramer acetate (Copaxone) treatment in relapsing-remitting MS: quantitative MR assessment.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900036-6

7 January 2021

Mitoxantrone immunotherapy in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900036-6

7 January 2021

Mechanisms of immunomodulation by glatiramer acetate

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900036-6

7 January 2021

Degeneracy, as opposed to specificity, in immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900036-6

7 January 2021

The neuroprotective effect of inflammation: implications for the therapy of multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900036-6

7 January 2021

A phase III trial of intramuscular recombinant interferon beta as treatment for exacerbating-remitting multiple sclerosis: design and conduct of study and baseline characteristics of patients. Multiple Sclerosis Collaborative Research Group (MSCRG).

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900036-6

7 January 2021

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900036-6

7 January 2021

Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years. Copolymer 1 Multiple Sclerosis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900036-6

7 January 2021

Glatiramer acetate (Copaxone) therapy induces CD8(+) T cell responses in patients with multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900036-6

7 January 2021

Dual action of glatiramer acetate (Cop-1) in the treatment of CNS autoimmune and neurodegenerative disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900036-6

7 January 2021

T cell immunity to copolymer 1 confers neuroprotection on the damaged optic nerve: possible therapy for optic neuropathies

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900036-6

7 January 2021

Natural history and clinical outcome measures for multiple sclerosis studies. Why at the present time does EDSS scale remain a preferred outcome measure to evaluate disease evolution?

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900036-6

7 January 2021

Effect of treatment with copolymer 1 (Cop-1) on the in vivo and in vitro manifestations of experimental allergic encephalomyelitis (EAE)

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900036-6

7 January 2021

Immunotherapy of multiple sclerosis: where are we? Where should we go?

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900036-6

7 January 2021

Treatment of multiple sclerosis with copolymer-1 (Copaxone): implicating mechanisms of Th1 to Th2/Th3 immune-deviation.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900036-6

7 January 2021

Multiple sclerosis: comparison of copolymer-1- reactive T cell lines from treated and untreated subjects reveals cytokine shift from T helper 1 to T helper 2 cells

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900036-6

7 January 2021

Progress in determining the causes and treatment of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900036-6

7 January 2021

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900036-6

1 reference

7 January 2021

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900036-6

7 January 2021

Characterization of T cell lines derived from glatiramer-acetate-treated multiple sclerosis patients

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900036-6

7 January 2021

Evidence of endogenous regulatory function of transforming growth factor-beta 1 in experimental allergic encephalomyelitis

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900036-6

7 January 2021

Vaccination for protection of retinal ganglion cells against death from glutamate cytotoxicity and ocular hypertension: implications for glaucoma

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900036-6

7 January 2021

Glatiramer acetate in the treatment of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900036-6

7 January 2021

BDNF and gp145trkB in multiple sclerosis brain lesions: neuroprotective interactions between immune and neuronal cells?

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900036-6

7 January 2021

Experimental allergic encephalomyelitis

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900036-6

7 January 2021

Experimental autoimmune encephalomyelitis in the rat: lessons in T-cell immunology and autoreactivity

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900036-6

7 January 2021

Specific inhibition of the T-cell response to myelin basic protein by the synthetic copolymer Cop 1

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900036-6

7 January 2021

Cross-reactions and specificities of monoclonal antibodies against myelin basic protein and against the synthetic copolymer 1

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900036-6

7 January 2021

Copolymer 1 inhibits chronic relapsing experimental allergic encephalomyelitis induced by proteolipid protein (PLP) peptides in mice and interferes with PLP-specific T cell responses

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900036-6

7 January 2021

Copolymer 1: from basic research to clinical application

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900036-6

7 January 2021

Immunomodulation of experimental autoimmune encephalomyelitis by oral administration of copolymer 1.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900036-6

7 January 2021

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900036-6

7 January 2021

Axonal pathology in multiple sclerosis: relationship to neurologic disability

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900036-6

7 January 2021

Polyreactive antibodies to glatiramer acetate promote myelin repair in murine model of demyelinating disease

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900036-6

7 January 2021

Glatiramer acetate (GA) induces IL-13/IL-5 secretion in naive T cells

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900036-6

7 January 2021

Matrix metalloproteinases and diseases of the CNS.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900036-6

7 January 2021

Identifiers

1 reference

26 June 2017

1 reference